公开(公告)号：US10168331B2

公开(公告)日：2019-01-01

申请号：US15304473

申请日：2015-04-02

Applicant: Randox Laboratories Ltd.

Inventor： Mark Ruddock ,  Cherith Reid ,  John Lamont ,  Stephen Fitzgerald ,  Ricardo De Matos Simoes ,  Kathleen Williamson

IPC: G01N33/574 ,  G01N33/68 ,  G01N33/543 ,  G01N33/577

Abstract: The present invention provides a method and a solid state device for identifying the presence of urothelial cancer in a patient comprising assigning the subject to a sub-population according to smoking habits, measuring the level of each biomarker of a panel of biomarkers in one or more samples obtained from the subject; and correlating the measured levels of the panel of biomarkers with the likelihood of the subject having urothelial cancer such that the subject can be classified as having urothelial cancer or as being a control.

公开(公告)号：US20140072987A1

公开(公告)日：2014-03-13

申请号：US14025623

申请日：2013-09-12

Applicant: RANDOX LABORATORIES LTD.

Inventor： Mark W. Ruddock ,  Cherith N. Reid ,  Kathleen Williamson ,  John V. Lamont ,  Stephen P. Fitzgerald

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/57407 ,  G01N2800/52 ,  G01N2800/60

Abstract: The disclosure relates to methods of detecting bladder cancer including assaying a patient sample for the levels of certain combinations of biomarkers. The disclosure also relates to methods for determining the efficacy of a drug for the treatment of bladder cancer.

Abstract translation: 本公开涉及检测膀胱癌的方法，包括测定患者样品中生物标志物的某些组合的水平。 本公开还涉及用于确定药物治疗膀胱癌的功效的方法。

公开(公告)号：US20220011311A1

公开(公告)日：2022-01-13

申请号：US17294358

申请日：2019-11-15

Applicant: Randox Laboratories Ltd.

Inventor： Mark Ruddock ,  John Lamont ,  Stephen Fitzgerald ,  Kathleen Williamson

IPC: G01N33/574

Abstract: The present invention provides a method for detecting the presence or risk of bladder cancer in a female patient comprising the steps of detecting the presence of a panel of biomarkers in a sample isolated from a female patient, said panel of biomarkers comprising IL-13 and IL-12p70 and one or more biomarkers selected from BTA, Midkine, PAI-1/tPA, 8OHdG, CEA, CK18, Clusterin, Creatinine, CXCL16, Cystatin B, Cystatin C, d-Dimer, EGF, FAS, HAD, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8, MCP-1, Microalbumin, MMP9NGAL, MMP9TIMP1, NGAL, NSE, Progranulin, TUP, TGFB1, Thrombomodulin, sTNFR1, TPA, VEGF and Triglycerides and/or the concentration of albumin/microalbumin/protein and creatinine expressed as an albumin:creatinine ratio in a sample isolated from a female patient; and assessing the results and comparing them to a normal control wherein an elevated presence of the biomarker compared to a normal control indicates the presence or risk of cancer in the patient from whom the sample is isolated.

公开(公告)号：US20170089900A1

公开(公告)日：2017-03-30

申请号：US15304473

申请日：2015-04-02

Applicant: Randox Laboratories Ltd.

Inventor： Mark Ruddock ,  Cherith Reid ,  John Lamont ,  Stephen Fitzgerald ,  Ricardo De Matos Simoes ,  Kathleen Williamson

IPC: G01N33/574 ,  G01N33/577 ,  G01N33/543

CPC classification number: G01N33/57407 ,  G01N33/543 ,  G01N33/57488 ,  G01N33/577 ,  G01N33/6869 ,  G01N2333/485 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/545

Abstract: The present invention provides a method and a solid state device for identifying the presence of urothelial cancer in a patient comprising assigning the subject to a sub-population according to smoking habits, measuring the level of each biomarker of a panel of biomarkers in one or more samples obtained from the subject; and correlating the measured levels of the panel of biomarkers with the likelihood of the subject having urothelial cancer such that the subject can be classified as having urothelial cancer or as being a control.